All updated as on -
The global Sprycel market is expected to rise from its 2023 valuation of US$5.69 billion to US$8.28 billion by 2030, expanding at a CAGR of 6.5%. Chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) are both treated with Sprycel (dasatinib), a targeted therapy medication. It is a second-generation tyrosine kinase inhibitor that prevents CML cells from multiplying by inhibiting the activity of the Bcr-Abl protein.
The worldwide prevalence of CML and Ph+ ALL is rising. The need for efficient therapies like Sprycel increases as more patients are diagnosed with these illnesses. Many individuals who were treated with Sprycel for CML or Ph+ ALL saw improvements in their symptoms and overall health. When administered properly, its safety profile makes it a top choice for many doctors and patients. Tyrosine kinase inhibitors (TKIs), of which Sprycel is a member, work by blocking the activity of particular proteins that contribute to the development and spread of cancer. The potential of targeted medicines like Sprycel to suppress cancer cell development while minimising damage to healthy cells is boosting their importance in cancer treatment. Patients with CML and Ph+ ALL have the potential to become resistant or intolerant to therapies like imatinib. Demand for Sprycel, which is typically administered as a secondary or tertiary treatment, is fueled by such situations.
Although Sprycel has only been approved to treat chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL), there is still room to investigate its potential in other haematological malignancies and solid tumours. Opportunities for Sprycel's therapeutic application in more areas may be discovered through further study and clinical testing. Potentially beneficial combinations include Sprycel with other targeted medicines, chemotherapeutic medications, or immunotherapies. Combining Sprycel with other treatments in clinical trials may reveal synergistic effects and boost its efficacy. Sprycel's market potential could be increased by the creation of efficient combination regimens.
Treatments that target specific molecular targets in cancer progression, like Sprycel, are gaining popularity. Targeted therapies are in high demand because they are more effective and have less negative side effects than standard chemotherapy, reflecting the current emphasis on personalised care and precision oncology. Emerging evidence and clinical research are constantly used to update the treatment guidelines for CML and Ph+ ALL. Healthcare providers' uptake and utilisation of Sprycel are affected by these guidelines. To ensure that Sprycel is being used in accordance with best practise methods, it is crucial to stay aware of the ever-evolving rules.
Patients and healthcare systems may face difficulty affording expensive targeted therapies like Sprycel. Sprycel's high cost could be a problem in areas where healthcare funding is scarce or where people do not have access to adequate insurance. Patient access to Sprycel may also be constrained by reimbursement barriers and limits imposed by payers. Increased price competition may result from the introduction of generic copies of Sprycel as patent exclusivity for the brand-name drug expires or is about to expire. Because generic alternatives are usually less expensive than brand-name drugs, they may threaten Sprycel's market dominance and financial success. Potential side effects and safety worries are there with Sprycel, as they are with any medicine. The risk of myelosuppression, haemorrhage, fluid retention, cardiovascular events, and pulmonary arterial hypertension exists. These side effects have the potential to decrease patient compliance, necessitate more frequent monitoring, and potentially cause patients to stop taking their medication altogether.
Report Coverage
Global Sprycel research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Sprycel report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Sprycel competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Sprycel market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Sprycel market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Sprycel market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Bristol-Myers Squibb (BMS), Novartis, Teva Pharmaceutical Industries, Mylan, Accord Healthcare, Sun Pharma, Dr. Reddy's Laboratories, Aurobindo Pharma
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Sprycel market based on the below-mentioned segments:
Global Sprycel Market, By Demographic
Age
Gender
Income
Global Sprycel market, By Psychographic
Lifestyle
Attitudes
Global Sprycel Market, By Behavioral
Usage Rate
Compliance
Treatment History
Global Sprycel market, Regional Analysis
The worldwide prevalence of CML and Ph+ ALL is rising. The need for efficient therapies like Sprycel increases as more patients are diagnosed with these illnesses. Many individuals who were treated with Sprycel for CML or Ph+ ALL saw improvements in their symptoms and overall health. When administered properly, its safety profile makes it a top choice for many doctors and patients. Tyrosine kinase inhibitors (TKIs), of which Sprycel is a member, work by blocking the activity of particular proteins that contribute to the development and spread of cancer. The potential of targeted medicines like Sprycel to suppress cancer cell development while minimising damage to healthy cells is boosting their importance in cancer treatment. Patients with CML and Ph+ ALL have the potential to become resistant or intolerant to therapies like imatinib. Demand for Sprycel, which is typically administered as a secondary or tertiary treatment, is fueled by such situations.
Although Sprycel has only been approved to treat chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL), there is still room to investigate its potential in other haematological malignancies and solid tumours. Opportunities for Sprycel's therapeutic application in more areas may be discovered through further study and clinical testing. Potentially beneficial combinations include Sprycel with other targeted medicines, chemotherapeutic medications, or immunotherapies. Combining Sprycel with other treatments in clinical trials may reveal synergistic effects and boost its efficacy. Sprycel's market potential could be increased by the creation of efficient combination regimens.
Treatments that target specific molecular targets in cancer progression, like Sprycel, are gaining popularity. Targeted therapies are in high demand because they are more effective and have less negative side effects than standard chemotherapy, reflecting the current emphasis on personalised care and precision oncology. Emerging evidence and clinical research are constantly used to update the treatment guidelines for CML and Ph+ ALL. Healthcare providers' uptake and utilisation of Sprycel are affected by these guidelines. To ensure that Sprycel is being used in accordance with best practise methods, it is crucial to stay aware of the ever-evolving rules.
Patients and healthcare systems may face difficulty affording expensive targeted therapies like Sprycel. Sprycel's high cost could be a problem in areas where healthcare funding is scarce or where people do not have access to adequate insurance. Patient access to Sprycel may also be constrained by reimbursement barriers and limits imposed by payers. Increased price competition may result from the introduction of generic copies of Sprycel as patent exclusivity for the brand-name drug expires or is about to expire. Because generic alternatives are usually less expensive than brand-name drugs, they may threaten Sprycel's market dominance and financial success. Potential side effects and safety worries are there with Sprycel, as they are with any medicine. The risk of myelosuppression, haemorrhage, fluid retention, cardiovascular events, and pulmonary arterial hypertension exists. These side effects have the potential to decrease patient compliance, necessitate more frequent monitoring, and potentially cause patients to stop taking their medication altogether.
Report Coverage
Global Sprycel research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Sprycel report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Sprycel competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Sprycel market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Bristol-Myers Squibb (BMS), Novartis, Teva Pharmaceutical Industries, Mylan, Accord Healthcare, Sun Pharma, Dr. Reddy's Laboratories, Aurobindo Pharma |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Sprycel Market from 2021 to 2030.
- Market Forecast for Sprycel Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Sprycel competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Sprycel
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Sprycel market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Sprycel market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Bristol-Myers Squibb (BMS), Novartis, Teva Pharmaceutical Industries, Mylan, Accord Healthcare, Sun Pharma, Dr. Reddy's Laboratories, Aurobindo Pharma
Primary Target Market
- Market Players of Sprycel
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Sprycel market based on the below-mentioned segments:
Global Sprycel Market, By Demographic
Age
Gender
Income
Global Sprycel market, By Psychographic
Lifestyle
Attitudes
Global Sprycel Market, By Behavioral
Usage Rate
Compliance
Treatment History
Global Sprycel market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive sprycel market market research and competitor analysis for your business to help you develop more profound insights into the sprycel market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the sprycel market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.